As announced in our third-quarter presentation on November 27, 2024, and reaffirmed in our fourth-quarter presentation on February 12, 2025, Avance Gas has completed the sale of all its assets and has ...

Santhera Pharmaceuticals (SIX: SANN) announces the latest progress on the commercial rollout of AGAMREE® for the treatment of Duchenne Muscular Dystrophy (DMD). Funding ...

Santhera Pharmaceuticals (SIX: SANN) announces the latest progress on the commercial rollout of AGAMREE® for the treatment of Duchenne Muscular Dystrophy (DMD). Funding from National Health Service ...

Learn more about whether Amarin Corporation plc or Catalyst Pharmaceuticals, Inc. is a better investment based on AAII's A+ ...

We recently published a list of 11 Best Russell 2000 Stocks to Buy According to Wall Street Analysts. In this article, we are ...

Health Canada granted priority review to an application seeking approval of vamorolone, marketed in the U.S. as Agamree, for ...

Catalyst Pharmaceuticals (CPRX) reported that its sub-licensee in Canada, Kye Pharmaceuticals, has announced that Health Canada has accepted ...

Kye Pharmaceuticals announced it has submitted a New Drug Submission, or NDS, to Health Canada for the regulatory review and approval of ...

Kye Pharmaceuticals, Inc. ("Kye") announced today it has submitted a New Drug Submission (NDS) to Health Canada for the ...

Sarepta and Roche announced a 16-year-old US patient dosed with Elevidys died of acute liver failure in March 2025.

Dario Eklund, CEO of Santhera said: “The last 12 months have been a pivotal period for both the Company and DMD patients, as we began the global commercial roll-out of AGAMREE. Today, we are pleased ...

Her experience would be invaluable as we continue the rollout of AGAMREE® in new markets and evaluate opportunities to further expand our portfolio. Dr. Rolli's nomination follows the recent ...